hotspot -WSS

hotspot

author：Wikipedia 2025-09-06 01:24:49 - browse：7872

The experimental Alzheimer’s drug lecanemab, hailed after it slowed patients’ cognitive decline in a clinical trial, may have contributed to the death in June of a patient in the study, STAT has learned.

One investigator on the study flagged the death, noting it came after the patient experienced bleeding in the brain, and concluded it was related to the drug, according to documents obtained by STAT. Eisai, the drugmaker behind lecanemab, disagreed, pointing to other possible factors, including a series of setbacks in preceding months — multiple falls, a heart attack, a respiratory infection, and mini-stroke-like events.

Though still under investigation, the death suggests that new medicines to treat Alzheimer’s, like medicines to treat anything else, will come with their own side effects and costs. It also raises the importance of waiting for the full lecanemab data before drawing conclusions based on the positive press release put out by Eisai and its partner Biogen last month.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： What Congress can do to address the rural doctor shortage

WSS

Emergency medicine has repudiated 'excited delirium.' Now what?

FDA panel to weigh approval of NurOwn, controversial ALS drug

Eli Lilly to pay $200M for Beam’s stake in gene

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

WHO may add ‘noma' to its list of neglected tropical diseases

Second xenotransplant done with gene

leisure time

hotspot

hotspot

Virginia high school admissions case could be legal follow

First Opinion Podcast: How to protect health care in times of war

George Santos makes 1st court appearance after pleading not guilty to 13 counts

EpiPen alternative approval delay highlights citizen petition issue

United colonoscopy coverage change 'may cost lives,' doctors say

CDC's new outbreak response network to include Northeastern

Psychedelics group wrestles with new pharma identity

Emergency medicine has repudiated 'excited delirium.' Now what?

Cancer drug shortages should be causing more outrage

The FDA weighs the risks of candy

entertainment

Intarcia’s device

Biden's order seeks to regulate AI risk without stifling innovation

First Opinion Podcast: How to protect health care in times of war

Paying for Covid pills will soon shift to insurers

Medtronic CEO on promising devices for diabetes, hypertension

WHO may add ‘noma' to its list of neglected tropical diseases

Wikipedia

hotspot

hotspot

hotspot